O	0	12	Prophylactic
O	13	16	use
O	17	19	of
B-intervention	20	27	Mepitel
I-intervention	28	32	Film
O	33	41	prevents
B-condition	42	51	radiation
I-condition	51	52	-
I-condition	52	59	induced
I-condition	60	65	moist
I-condition	66	78	desquamation
O	79	81	in
O	82	84	an
O	85	90	intra
O	90	91	-
O	91	98	patient
O	99	109	randomised
O	110	120	controlled
O	121	129	clinical
O	130	135	trial
O	136	138	of
B-total-participants	139	141	78
O	142	148	breast
O	149	155	cancer
O	156	164	patients
O	164	165	.

O	166	173	Safetac
O	173	174	-
O	174	179	based
O	180	184	soft
O	185	193	silicone
O	194	203	dressings
O	204	208	used
O	209	211	in
O	212	213	a
O	214	224	management
O	225	232	setting
O	233	241	decrease
O	242	245	the
O	246	254	severity
O	255	257	of
O	258	267	radiation
O	267	268	-
O	268	275	induced
O	276	281	acute
O	282	286	skin
O	287	296	reactions
O	297	300	but
O	301	303	do
O	304	307	not
O	308	314	affect
O	315	320	moist
O	321	333	desquamation
O	334	339	rates
O	339	340	.

O	341	345	Here
O	346	348	we
O	349	360	investigate
O	361	364	the
O	365	377	prophylactic
O	378	381	use
O	382	384	of
O	385	392	another
O	393	400	Safetac
O	401	408	product
O	408	409	,
O	410	417	Mepitel
O	418	422	Film
O	422	423	,
O	424	426	on
O	427	432	moist
O	433	445	desquamation
O	446	451	rates
O	451	452	.

O	453	454	A
O	455	460	total
O	461	463	of
B-total-participants	464	466	80
B-eligibility	467	473	breast
I-eligibility	474	480	cancer
I-eligibility	481	489	patients
I-eligibility	490	499	receiving
I-eligibility	500	509	radiation
I-eligibility	510	517	therapy
O	518	522	were
O	523	532	recruited
O	533	540	between
O	541	548	October
O	549	553	2012
O	554	557	and
O	558	563	April
O	564	568	2013
O	568	569	;
B-total-participants	570	572	78
O	573	585	participants
O	586	597	contributed
O	598	602	data
O	603	606	for
O	607	615	analysis
O	615	616	.

O	617	624	Lateral
O	625	628	and
O	629	635	medial
O	636	642	halves
O	643	645	of
O	646	649	the
O	650	654	skin
O	655	660	areas
O	661	663	to
O	664	666	be
O	667	677	irradiated
O	678	682	were
O	683	693	randomised
O	694	696	to
O	697	704	Mepitel
O	705	709	Film
O	710	712	or
B-control	713	720	aqueous
I-control	721	726	cream
O	726	727	;
O	728	732	skin
O	733	737	dose
O	738	741	was
O	742	750	measured
O	751	756	using
O	757	774	thermoluminescent
O	775	785	dosimeters
O	785	786	;
O	787	791	skin
O	792	800	reaction
O	801	809	severity
O	810	813	was
O	814	822	assessed
O	823	828	using
O	829	835	RISRAS
O	836	839	and
O	840	844	RTOG
O	845	851	scales
O	851	852	.

O	853	860	Overall
O	861	865	skin
O	866	874	reaction
O	875	883	severity
O	884	887	was
O	888	895	reduced
O	896	898	by
O	899	901	92
O	901	902	%
O	903	904	(
O	904	905	p
O	905	906	<
O	906	907	0
O	907	908	.
O	908	912	0001
O	912	913	)
O	914	916	in
O	917	923	favour
O	924	926	of
O	927	934	Mepitel
O	935	939	Film
O	940	941	(
O	941	947	RISRAS
O	947	948	)
O	948	949	.

O	950	953	All
O	954	962	patients
O	963	972	developed
O	973	977	some
O	978	982	form
O	983	985	of
B-outcome	986	994	reaction
I-outcome	995	997	in
I-outcome	998	1003	cream
I-outcome	1003	1004	-
I-outcome	1004	1011	treated
I-outcome	1012	1016	skin
O	1017	1022	which
O	1023	1033	progressed
O	1034	1036	to
O	1037	1042	moist
O	1043	1055	desquamation
O	1056	1058	in
B-cv-bin-percent	1059	1061	26
I-cv-bin-percent	1061	1062	%
O	1063	1065	of
O	1066	1074	patients
O	1075	1076	(
B-outcome	1076	1080	RTOG
I-outcome	1081	1087	grades
I-outcome	1088	1089	I
O	1089	1090	:
B-cv-bin-percent	1091	1093	28
I-cv-bin-percent	1093	1094	%
O	1094	1095	;
B-outcome	1096	1099	IIA
O	1099	1100	:
B-cv-bin-percent	1101	1103	46
I-cv-bin-percent	1103	1104	%
O	1104	1105	;
B-outcome	1106	1109	IIB
O	1109	1110	:
B-cv-bin-percent	1111	1113	18
I-cv-bin-percent	1113	1114	%
O	1114	1115	;
B-outcome	1116	1119	III
O	1119	1120	:
B-cv-bin-percent	1121	1122	8
I-cv-bin-percent	1122	1123	%
O	1123	1124	)
O	1124	1125	.

O	1126	1130	Only
B-iv-bin-percent	1131	1133	44
I-iv-bin-percent	1133	1134	%
O	1135	1137	of
O	1138	1146	patients
O	1147	1150	had
O	1151	1152	a
B-outcome	1153	1157	skin
I-outcome	1158	1166	reaction
O	1167	1172	under
O	1173	1176	the
O	1177	1181	Film
O	1181	1182	,
O	1183	1188	which
O	1189	1192	did
O	1193	1196	not
O	1197	1205	progress
O	1206	1208	to
O	1209	1214	moist
O	1215	1227	desquamation
O	1228	1230	in
O	1231	1234	any
O	1235	1237	of
O	1238	1241	the
O	1242	1250	patients
O	1251	1252	(
B-outcome	1252	1256	RTOG
I-outcome	1257	1263	grades
I-outcome	1264	1265	I
O	1265	1266	:
B-iv-bin-percent	1267	1269	36
I-iv-bin-percent	1269	1270	%
O	1270	1271	;
B-outcome	1272	1275	IIA
O	1275	1276	:
B-iv-bin-percent	1277	1278	8
I-iv-bin-percent	1278	1279	%
O	1279	1280	)
O	1280	1281	.

O	1282	1289	Mepitel
O	1290	1294	Film
O	1295	1305	completely
O	1306	1315	prevented
O	1316	1321	moist
O	1322	1334	desquamation
O	1335	1338	and
O	1339	1346	reduced
O	1347	1351	skin
O	1352	1360	reaction
O	1361	1369	severity
O	1370	1372	by
O	1373	1375	92
O	1375	1376	%
O	1377	1381	when
O	1382	1386	used
O	1387	1403	prophylactically
O	1404	1406	in
O	1407	1410	our
O	1411	1417	cohort
O	1417	1418	.
